MREO

Mereo BioPharma

MREO

Market cap $302M

Overview Fund Trends Analyst Outlook Journalist POV

1.90 USD

+0.01

0.53%

At close Updated Oct 31, 4:00 PM EDT

Pre-market

After hours

1.92

+0.02

1.05%

1 day

0.53%

5 days

-5.94%

1 month

-7.77%

3 months

12.43%

6 months

-26.64%

Year to date

-44.44%

1 year

-54.87%

5 years

-21.81%

10 years

-70.77%

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 36

Healthcare Biotechnology